the pathway to
clinical trials with
upper hand in
arms race between
humans and pathogens
T CELL RECEPTORS
& UNLOCK A NEW
WORLD OF IMMUNE
T Cell Receptors (TCRs) constitute one of the most promising classes of emerging therapeutics. Whilst TCRs are amongst the most complex facets of immune biology, engineering of an optimum T Cell Receptor can transform immunotherapies and personalised medicines.
Etcembly is building the world’s largest machine learning database and unmatched immunology expertise to deliver the safest and most powerful TCR immunotherapies through rapid computer-assisted engineering.
APPROACHING THE CHALLENGE
The TCR repertoire at any time point reflects on the person’s health and contains a memory of all past experiences. However, TCRs are highly variable and their activities aren’t easily predictable with traditional empirical methods.
Data on a new TCR candidate should not only validate affinity, but also deliver exhaustive confirmation of every possibility of off-target, cross-reactive, or toxicity binding events.
By understanding an increasing database of TCR repertoires, Etcembly will be able to develop tools to assess immune health and identify disease biomarkers.
Our AI platform learns from the pattern of T cell target interactions and identifies T Cell Receptors that can be used to treat specific diseases in the clinic.
Etcembly has developed a proprietary machine learning platform - EMLy™ - trained and optimised to find deeply complex patterns in TCR repertoires. By leveraging this diversity, our AI, governed by biophysics, validated and optimised through empirical results, will lead to effective design of personalised therapeutics.
By employing our three-faceted TCR discovery platform, engineered to compress timelines and deliver rapid unbiased insights, your immune-based therapy will have the highest chance of success in specificity and efficacy in the quickest time possible.
safe and potent
TCRs for the clinic
diagnostics that identify the
right patient population
how the immune system is driven by external factors
such as ethnicity
across all patient groups
THREE PILLARS TO SUCCESS
1: A well-trained, highly specific Machine Learning platform will explore the entire universe of possibilities, quickly identifying the highest potential TCR candidates that have the highest affinity and lowest probability of cross-reactivity, off-target or toxicity events.
2. Data-guided empirical optimisation cycles and engineering will rapidly develop ideal TCR candidate(s) and eliminate adverse effects.
3. Rigorous in vitro validation will provide the predictive confidence that the ideal TCR candidate is clinically safe and potent.
Data extraction on public domains
Structural analysis of pHLA:TCR
DEEP NEURAL ARCHITECTURE
INTEGRATED WITH THE DATABASE
form the basis of EMLy’s computation in novel
diagnostic and theraputic solutions.
of patient derived
T cells (public domain and proprietry)
TCR Sequencing data (public domain and proprietry)
3D structural modelling
Profile biomarkers for treatment selection and outcome prediction
optimised T cell and neoantigen-directed immunotherapies
Personalised immunotherapy design
ETCer Etcembly T Cell Engaging Receptor Programs
20 years of R&D experience covering pipeline from discovery to translational medicine in Immunocore & AstraZeneca
25 years of experience in translational medicine, TCR and antibody repertoire analytics
Over 20 years of experience developing TCR-based therapeutics at Immunocore and Adaptimmune
25 years of experience in
Pharma Biotech sector including senior BD roles in Chroma Therapeutics, Ipsen and ValoTx
Over 15 years of multi-discipline finance experience, including
10 years in Biopharma
Serial entrepreneur. Founder of Cambridge Antibody Technology, Maxion Therapeutics and IonTas
Physician with 37 years’ industry experience of drug development, the last 10 years in TCR T-cell therapy at Adaptimmune and consulting for other Biotechs
Kennedy Professor of Translational Rheumatology at the University of Oxford, and Director of Clinical Research at the Kennedy Institute of Rheumatology
Serial founder and investor with considerable Board experience, including Immunocore, Adaptimmune, Oxford Asymmetry and Oxford Semiconductor Ltd
TCR therapies pioneer.
Founded Immunocore and Adaptimmune
If you are as excited about our journey as
we are, then please drop us an email.
We are committed to developing the next generation of scientists and welcome motivated individuals who share our vision. If you aspire to break boundaries in precision medicine and are able to demonstrate understanding in the convergence of these fields, we are interested in hearing from you.
Get in touch here